KRAS GENE MUTATION
Clinical trials for KRAS GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS GENE MUTATION trials appear
Sign up with your email to follow new studies for KRAS GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat cancers with gene mutations
Disease control OngoingThis early-phase study tests a drug called neratinib combined with one of three other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors with specific gene changes (EGFR, …
Matched conditions: KRAS GENE MUTATION
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New hope for tough colorectal cancer: drug combo shows promise
Disease control OngoingThis study tests two drugs, panitumumab and trametinib, in people with stage IV colorectal cancer that no longer responds to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 59 participants will receive either panitumumab alone…
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New combo therapy targets tough lung cancer mutation
Disease control OngoingThis study tested a combination of two drugs, trametinib and docetaxel, in 60 people with a specific genetic subtype of advanced lung cancer (KRAS mutation) that had worsened after prior treatments. The goal was to see if the combination could shrink tumors. The approach uses one…
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
New drug targets tough lung cancer mutation in small trial
Disease control OngoingThis study tests an experimental drug called TVB-2640 in 18 adults with a specific type of advanced lung cancer (KRAS-mutant NSCLC) that has not responded to standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing over 8 weeks. Researchers …
Matched conditions: KRAS GENE MUTATION
Phase: PHASE2 • Sponsor: David E Gerber • Aim: Disease control
Last updated Jun 03, 2026 12:06 UTC